← Lic Mutual Fund

LIC MF Healthcare Fund-Direct Plan-Growth

Equity Data as of Apr 2026 Comparing Mar 2026 → Apr 2026
Share: WhatsApp X
Stocks Held
26
Apr 2026
Equity Holdings
₹81.25 Cr
Equity only, excl. debt & cash
Top 5 Weight
34.1%
Moderate
Top 10 Weight
55.7%
Moderate
Changes
26
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
68.8% of portfolio
📋 What Happened This Month Among existing holdings, Neuland Laboratories Limited saw the biggest increase — now at 4.59% of the portfolio. Torrent Pharmaceuticals Limited was trimmed the most, now at 6.50%. Sun Pharmaceutical Industries Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 68.8%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Feb 2026 Mar 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 67.8% 69.2% +1.5%
Healthcare Services 23.8% 22.2% -1.5%
Chemicals & Petrochemicals 4.7% 4.7% +0.0%
Mar 2026 Apr 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 69.2% 68.8% -0.4%
Healthcare Services 22.2% 22.6% +0.4%
Chemicals & Petrochemicals 4.7% 4.7% 0.0%
Biggest Add
Neuland Laboratories Limited
+0.62% · now 4.59%
Biggest Trim
Torrent Pharmaceuticals Limited
-0.58% · now 6.50%

What Changed?

Comparing Mar 2026 → Apr 2026

Mar 2026 Apr 2026
↑ 14 Increased ↓ 12 Decreased
#StockSectorMar 2026Apr 2026Change
1
Neuland Laboratories Limited
₹3.88 Cr
Pharmaceuticals & Biotechnology 3.97% 4.59% +0.62%
2
Onesource Specialty Pharma Limited
₹3.85 Cr
Pharmaceuticals & Biotechnology 4.17% 4.56% +0.39%
3
Piramal Pharma Limited
₹3.66 Cr
Pharmaceuticals & Biotechnology 3.94% 4.33% +0.39%
4
Fortis Healthcare Limited
₹3.97 Cr
Healthcare Services 4.37% 4.70% +0.33%
5
Artemis Medicare Services Limited
₹2.28 Cr
Healthcare Services 2.45% 2.70% +0.25%
6
Anthem Biosciences Limited
₹1.93 Cr
Pharmaceuticals & Biotechnology 2.12% 2.28% +0.16%
7
Glenmark Pharmaceuticals Limited
₹2.89 Cr
Pharmaceuticals & Biotechnology 3.27% 3.41% +0.14%
8
Global Health Limited
₹1.67 Cr
Healthcare Services 1.84% 1.98% +0.14%
9
Concord Biotech Limited
₹2.34 Cr
Pharmaceuticals & Biotechnology 2.67% 2.77% +0.10%
10
Navin Fluorine International Limited
₹2.81 Cr
Chemicals & Petrochemicals 3.24% 3.32% +0.08%
#StockSectorMar 2026Apr 2026Change
1
Torrent Pharmaceuticals Limited
₹5.50 Cr
Pharmaceuticals & Biotechnology 7.08% 6.50% -0.58%
2
Sun Pharmaceutical Industries Limited
₹9.48 Cr
Pharmaceuticals & Biotechnology 11.77% 11.22% -0.55%
3
IPCA Laboratories Limited
₹2.54 Cr
Pharmaceuticals & Biotechnology 3.40% 3.01% -0.39%
4
Apollo Hospitals Enterprise Limited
₹5.51 Cr
Healthcare Services 6.84% 6.52% -0.32%
5
Abbott India Limited
₹2.46 Cr
Pharmaceuticals & Biotechnology 3.20% 2.91% -0.29%
6
Alkem Laboratories Limited
₹2.70 Cr
Pharmaceuticals & Biotechnology 3.39% 3.20% -0.19%
7
Gland Pharma Limited
₹2.46 Cr
Pharmaceuticals & Biotechnology 3.04% 2.91% -0.13%
8
Acutaas Chemicals Ltd
₹1.63 Cr
Pharmaceuticals & Biotechnology 2.06% 1.93% -0.13%
9
Vinati Organics Limited
₹1.16 Cr
Chemicals & Petrochemicals 1.48% 1.37% -0.11%
10
Max Healthcare Institute Limited
₹1.67 Cr
Healthcare Services 2.06% 1.97% -0.09%

Full Portfolio

26 stocks — Apr 2026

# Stock Sector Cap Weight & Value
1
₹9.48 Cr
Pharmaceuticals & Biotechnology
11.22%
2
₹5.51 Cr
Healthcare Services
6.52%
3
₹5.50 Cr
Pharmaceuticals & Biotechnology
6.50%
4
₹4.35 Cr
Pharmaceuticals & Biotechnology
5.15%
5
₹4.00 Cr
Pharmaceuticals & Biotechnology
4.74%
6
₹3.97 Cr
Healthcare Services
4.70%
7
₹3.88 Cr
Pharmaceuticals & Biotechnology
4.59%
8
₹3.85 Cr
Pharmaceuticals & Biotechnology
4.56%
9
₹3.66 Cr
Pharmaceuticals & Biotechnology
4.33%
10
₹2.89 Cr
Pharmaceuticals & Biotechnology
3.41%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 Lic Mutual Fund — Portfolio & Holdings
See all funds managed by Lic Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.